Idiopathic pseudotumours of the pterygopalatine fossa: case series and a narrative review by Khan MK et al.
CASE SERIES REVIEW
Idiopathic pseudotumours of the pterygopalatine fossa: 
case series and a narrative review*
Abstract 
Background: Idiopathic pseudotumour (IP) is a non-specific, non-neoplastic, inflammatory process without identifiable local or 
systemic causes. IP in the head and neck region present diagnostic and management issues. 
Methodology: Retrospective case series and literature review.
Results: We describe clinical history, examination, laboratory investigations and image findings of three patients, all males who 
presented with facial pain and ophthalmoplegia. Scans revealed lesions in the pterygopalatine fossa. The diagnosis of idiopathic 
pseudotumour was confirmed by histopathology. We discuss their treatment pathways and prognosis.
Conclusions: Idiopathic pseudotumours in the head and neck region especially those involving anterior skull base are rare. 
Understanding their presentation and characteristics might help an unsuspecting otorhinolaryngologist in the diagnosis and 
treatment of these lesions.
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Introduction
Idiopathic pseudotumour (IP) is a rare nonspecific, non-neoplas-
tic inflammatory process without identifiable local or systemic 
cause (1). IP is not a single entity but an umbrella term for any 
nonspecific chronic inflammatory expansile lesion(2). Whilst more 
frequently in the lungs and orbit, they have also been described 
in other anatomic sites including the peritoneum, extremities, 
temporal bones, salivary glands, upper aerodigestive tracts and 
the skull base(3). The head and neck lesions are rare, accounting 
for 15% of all sites with <5% involving extra-orbital sites(2,4). 
Busse and Hocheim first described a form of head and neck IP in 
1903. The term ‘pseudotumour’ was first coined by Birch-Hirsch-
field in 1905 because of its locally aggressive but non-neoplastic 
nature(1).
IP can affect any age group and have been described in both 
sexes. Unilaterality is the norm but synchronous lesions have
 been described in the literature(5). These lesions present 
numerous challenges in their diagnosis and management and 
hence are relevant to the practice of most otolaryngologists. We 
present our experience with three pterygopalatine fossa lesions 
and our review of the relevant literature.
Methodology
We reviewed three case studies of patients with pseudotumours 
of the pterygopalatine fossa presenting to the Department 
of Otolaryngology - Head & Neck Surgery, Freeman Hospital, 
Newcastle upon Tyne, UK. For literature review, a Medline search 
was performed using keywords: pseudotumour, skull base, 
head and neck. The results were filtered for human studies and 
English language literature. Ninety-eight studies were identified. 
Abstracts were searched manually for appropriate studies for 
this review.
List of abbreviations: IP - Idiopathic pseudotumour(s); STIR - Short tau inversion recovery
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Case 1
A 59-year-old male initially presented with flashes of light and 
reduced vision in the right eye to a local ophthalmology depart-
ment. The symptoms improved spontaneously and the exami-
nation including intra-ocular pressure, fundoscopy and field test 
were unremarkable. 
Two years later he again presented as an emergency to the 
ophthalmology and neurosurgical teams with sudden visual 
disturbance in the right eye, drooping upper eyelid and right 
retro-orbital pain radiating to the right maxillary region. He had 
previous medical history of ischaemic heart disease and had 
undergone coronary artery bypass graft. On examination he had 
partial right ptosis, restricted adduction, elevation and depressi-
on on the right consistent with partial 3rd and 6th nerve palsies 
with pupillary sparing. All routine blood tests were normal. CT 
scan of the brain and orbit revealed a mass in the right pterygo-
palatine fossa. MRI of the paranasal sinuses showed extension 
of the disease process into posterior orbit (Figure 1). The patient 
was referred to the ENT department where fullness at the pos-
terior end of middle turbinate was noted. A transnasal approach 
was used for biopsy and debulking. The procedure was unevent-
ful and the biopsies showed fibrous tissue containing patchy 
chronic inflammation. Mixture of small lymphocytes, plasma 
cells and histiocytes were seen. The fibrous tissue was pauci-
cellular and densely hyalinised. Immunohistochemistry (CD79a, 
CD3, IgG and IgG4) showed few inflammatory cells. There was 
no evidence to suggest malignancy or IgG4 related disease 
process. There was further deterioration of visual acuity and 
retro-orbital pain and the examination revealed pale right optic 
disc and impaired colour vision to Ishihara chart testing. The 
patient was diagnosed with pseudotumour of the right pterygo-
palatine fossa with right orbital apex syndrome. Prednisolone 
was commenced at 60mg daily for two weeks. Pain improved 
initially but the vision deteriorated further with profound colour 
vision loss in the right eye. The steroids were reduced to 10mg 
daily with tapering dose of 2mg daily over 6 weeks. At his last 
appointment 6 months after his initial presentation there was 
no further deterioration of his vision and was pain free. Further 
care is on-going.
Case 2
A 37-year-old male initially presented with left facial pain with 
occasional blurring of vision and diplopia. On examination his 
visual acuity was 6/5 on the right and 6/6 on the left. He had 
slight restriction of left eye movements and mild ptosis. The rest 
of examination including intra-ocular pressure, fundoscopy, 
Goldman visual field test and colour vision were normal. His rou-
tine blood tests including inflammatory markers were normal. 
CT scan revealed a left pterygopalatine fossa lesion (Figure 2). A 
Caldwell Luc approach was used to biopsy the lesion. The biopsy 
showed features consistent with an inflammatory sclerosing 
process. After a debulking procedure there was significant im-
provement in his symptoms and ptosis. 5 months later he again 
developed pain around his left eye but ocular examination was 
Figure 1. A. T1 W axial MRI showing hypointense lesion (*) in the right pterygopalatine fossa involving the right orbital apex. B. T1 W coronal MRI 
showing a hypointense lesion suggesting a combination of fibrosis and attenuated cellularity. These lesions may show marked Gadolinium enhance-
ment.
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normal. Two months later the pain got worse and started to ra-
diate to the maxillary area. His visual acuity had reduced to 6/12 
in his left eye. He developed slight restriction of his extra-ocular 
movements and there was mild ptosis. Optic nerve function 
was intact. The patient declined the offer of systemic steroids. 
3 months later there was worsening of his headache and facial 
pain. His visual acuity had deteriorated to 8/18-1 on the left side. 
He also had developed central scotoma with enlarged blind 
spot and relative afferent pupillary defect. The colour vision had 
also reduced. An MRI scan was repeated which showed progres-
sion of disease. Intravenous steroids were commenced followed 
by a course of oral Prednisolone. There was no improvement 
with systemic steroids after a week and he was commenced on 
Azathioprine 50mg twice daily and Prednisolone was conti-
nued with 40mg daily. The visual acuity was reduced to finger 
counting at 1 meter only. The painful ophthalmoplegia got 
significantly worse and left medial wall orbital decompression 
was attempted for symptom relief. The ptosis improved but the 
pain persisted. His visual acuity was measured at 6/60 in the left 
eye. The patient had no evidence of residual disease or pro-
gression on his repeat MRI scan 1 year after his decompression 
procedure.
 
Case 3
A 50 years old male presented with 8 weeks history of left sided 
eye pain radiating to face, crackling sound in left ear and inter-
mittent dizziness. On examination he had a pupillary sparing 
left 3rd nerve palsy and proptosis. The rest of the ear, nose and 
throat examination including endoscopy was normal. CT and 
MRI revealed a mass in the left pterygopalatine fossa extending 
into infratemporal fossa, left cavernous sinus and abutting the 
left optic nerve. There was no bone involvement, MRI short tau 
inversion recovery (STIR) sequence showed no enhancement. 
Radiological findings were consistent with fibrosis. 
Autoantibodies screen, Immunoglobulins, plasma electrophore-
sis, acetylcholine esterase were all normal. Chest X-ray was also 
unremarkable. 
A Caldwell Luc approach was used to biopsy the lesion. It was 
noted that fat in the pterygopalatine fossa was replaced by a 
solid mass of tissue with areas of hard candlewax consistency. 
Histology confirmed idiopathic fibrotic changes only. There were 
no adverse features. The biopsy was repeated but again showed 
similar changes.
The patient was started on high dose corticosteroids for 4 
weeks, which brought significant symptom control. The visual 
impairment improved as well and the corticosteroids were 
tapered over the next three weeks and then continued at 15 
milligrams once daily. The total course was for five months. An 
MRI three months later showed improvement but no reso-
lution. A third follow up scan was arranged 6 months later, 
which remained the same. At his last follow up 12 years later 
the patient remained asymptomatic and there was no further 
progression of the disease. 
Figure 2. A. Axial CT scan showing homogeneous lesion in the left pterygopalatine fossa (black arrow). B. T1 W coronal MRI confirming hypointense 
lesion (Asterix) in left pterygopalatine fossa extending into left orbit. Hypointensity on T1 and T2 images helps differentiate IP from skull base neo-
plasms which are characteristically iso or hyperintense.
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Discussion
Idiopathic pseudotumour or inflammatory pseudotumours 
involving the skull base are rare. However, due to their anatomic 
location and considerable morbidity they are extremely impor-
tant. In contrast to the orbital variant, these are clinically more 
aggressive and present numerous challenges in their diagnosis 
and treatment(6).
Aetiology
The exact cause is still unknown. Multiple theories about the 
pathogenesis have been postulated.
a. Autoimmune reaction
Some authors believe IP are caused by an autoimmune reaction 
mediated by both B and T lymphocytes(1). A subgroup of these 
patients has a type of IgG4 related sclerosing disease that can 
also present with autoimmune pancreatitis and sclerosing siala-
denitis as well as IP(4).
b. Infection
An infectious process such as sinusitis or syphilis could trigger 
IP. This is true of some patients presenting with acute history of 
lesion developing with associated upper respiratory tract infecti-
ons or other viral illnesses. However, no definitive organism has 
been reliably implicated in the disease process. Others believe 
that organisms like Epstein-Barr Virus (EBV), Human Herpes virus 
8, Human immune deficiency virus (HIV) could be the trigger(1).
c. Fibroproliferative disorders
The presence of clonal cytogenic abnormalities supports the 
theory of fibroproliferative neoplastic origin of these lesions(7).
d. Trauma
The development of IP after instrumental manipulation has led 
some authors to believe that a dramatic tissue response in some 
patients lead to the formation of an exuberant inflammatory 
reaction with secondary tissue proliferation(8).
Presentation
Presentation depends on the site of the lesion. Orbital pseudo-
tumours usually present with painful ophthalmoplegia while 
extra-orbital lesions could present with cranial nerve palsies, 
facial pain, dysphagia, hearing loss, otalgia or nasal obstruction. 
Constitutional symptoms such as fever, anorexia, weight loss, 
malaise and somnolence have been reported in 15 to 30% of 
patients with IP(9).
Cranial nerve palsies result from direct nerve compression or 
extensive primary neural involvement, which may be acute or 
sub-acute(4,9,10).
Associations
The relationship between IP and diabetes has not been reported 
consistently. The increased susceptibility to infection with an al-
teration of immunity in diabetic patients might be one possible 
explanation(6).
Laurenzo and Graham noted that 23% of patients develop 
fibrosclerosing lesions at other sites including retroperitoneal fi-
brosis, orbital pseudotumour, sclerosing cholangitis and medias-
tinal fibrosis(11). They recommended routine screening for these 
lesions with liver function tests and CT chest and abdomen.
Diagnostic evaluation
For any head and neck IP a thorough ear, nose and throat exa-
mination should include the neck, cranial nerves and ophthal-
mological assessment. Diagnosis is based on the histological 
features in light of clinical, laboratory and radiological findings. 
As part of routine workup, the following investigations should 
be considered:
a. Radiology
The radiological features of IP are nonspecific and not charac-
teristic(12). MRI is the modality of choice. In most, lesions will be 
hypointense on T1 and T2 weighted images and show marked 
Gadolinium enhancement. The hypointensity seen on T2 images 
likely reflects a combination of fibrosis and attenuated cellulari-
ty(10). Enhanced CT may show homo- or heterogeneity and hypo-
, iso- or hyperdensity. Ultrasound also shows variable pattern 
of echogenicity with ill-defined margins in aggressive lesions. 
Doppler ultrasound may show prominent vascularity(9).
Sinonasal IP have more aggressive appearance with bony chan-
ges including erosion, remodelling and sclerosis(12).
IP lesions of the skull base show marked T2 hypointensity which 
helps differentiate them from skull base neoplasms that typical-
ly show iso to hyperintensity on T2 weighted images. However, 
these features cannot distinguish IP from skull base osteomy-
elitis, paragangliomas, neuromas and other granulomatous 
disorders e.g. granulomatosis with polyangiitis and Langerhans 
cell histiocytosis(13).
PET-CT is sometimes considered, which shows a hypermetabolic 
lesion(14). Chest X-ray might be useful to rule out synchronous 
lung lesion and sarcoidosis(5).
b. Open biopsy
Depending on the site of lesion, open biopsies may be chal-
lenging. Often multiple biopsies are necessary to rule out other 
malignant neoplasms and inflammatory conditions(15). The 
biopsy may be attempted using transoral, transcervical or an 
endoscopic approach. Endoscopic approach should be consi-
dered first because of low morbidity. In our patients, we used 
combined endoscopic transnasal-transmaxillary and Caldwell 
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Luc approach to the pterygopalatine fossa. 
c. Histology
The characteristic histopathological features include mixed 
inflammatory infiltrate with polyclonal lymphocytes, macro-
phages, polymorphonuclear cells, plasma cells, eosinophils and 
histiocytes with variable fibrosis. Immunohistochemical stains 
are used to identify cell lines and help in the grading process. 
Histopathological grading is based on the variability of cellular 
infiltrate, stromal components, vascular changes and tissues 
involved. The three main categories include the lymphoid, gra-
nulomatous and sclerosing variety(1). Others divide these lesions 
into two main types:
a) Sclerosing type
b) Non-sclerosing type
i.    Lymphoid
ii.    Fibrotic
iii.    Mixed
The sclerotic lesions are locally more aggressive and respond 
poorly to therapy. They are often associated with multifocal 
sclerotic disease processes. Some evidence suggests that the 
sclerosing variant respond to steroids if the disease duration 
has been brief(16). Others believe that there is apparent relation-
ship between the age of the lesion and degree of cellularity or 
fibrosis(17,18). 
There is a wide variation in the histological patterns and hence 
various synonyms exist to describe these lesions including 
plasma cell granuloma, mast cell granuloma, xanthogranuloma, 
histiocytoma, inflammatory myofibroblastic / myofibrohistiocy-
tic proliferation. 
d. Blood tests
Once biopsied, the suspicion of an inflammatory process would 
suggest further tests including erythrocyte sedimentation 
rate (ESR), anti-Nuclear Antibody, anti-double stranded DNA, 
anti-Neutrophil Cytoplasmic Antibody (cANCA and pANCA), Res-
piratory Protein-R and serum protein electrophoresis. Syphilis 
serology and testing for HIV could be helpful in certain cases.
Treatment
Corticosteroids
High dose corticosteroid is the treatment of choice for orbital 
IP. The dramatic response seen in orbital lesions within 24 to 
72 hours is often considered a diagnostic test for orbital IP(1). 
Maombaerts et al. found that 78% of patients treated with high 
dose corticosteroids had an initial response but achieved cure in 
37% only. 52% had disease recurrence(20). Other studies have no-
ted a response rate of approximately 80% achieving remission 
in 40-50% of patients. Recurrence after cessation of treatment 
occurs in approximately 20% of cases(4). Extra orbital IP have a 
variable response to high dose corticosteroids as demonstrated 
by our patients. Poor response is seen in lesions with high de-
gree of fibrosis or sclerosis. Lesions with abundant lymphocytes 
and plasma cells are considered more sensitive. This feature has 
been observed in both orbital and extra orbital lesions(1,4,7,16,19). 
Weisman et al.(19) and Osguthorpe et al.(21) observed that the IP 
appear less likely to respond to steroids if the lesion has a more 
chronic course.
There is no standard dose or duration. Some authors recom-
mend using low dose steroids for 6 months to prevent recur-
rence or relapse(4,6).
Mangiardi et al. treated all their six patients with skull base IP 
with Prednisolone 1mg/kg/day maximum 60mg until symptom 
resolution and normalization of imaging studies(1). The dose was 
then tapered over 2 weeks. The duration of treatment ranged 
from 10 to 60 days prior to tapering. Three patients showed 
complete response while one had partial response but the 
disease was stable. One patient needed adjuvant chemotherapy 
with cyclophosphamide to stabilise the disease. One patient had 
a recurrence, which was treated again with corticosteroids.
Surgery
Surgical resection can be considered as an alternative treatment 
option(6). Ruaux and Williamson recommend surgery as first 
line treatment for lesions involving paranasal sinuses and the 
temporal bone(8,22,23).
If a lesion is easily accessible and can be excised completely 
with low risk of complications, most surgeons would consider 
surgery. However, in lesions of the skull base with cranial nerve 
palsies complete resection is difficult. More aggressive surgery 
carries high risk of functional and cosmetic defects. Therefore, 
the risk of surgery should be weighed up against the risk of 
complications and discussed with the patient.
Radiation
Radiation treatment is considered for patients resistant to corti-
costeroid therapy or those who are unable to tolerate corticoste-
roids. However, some authors question the role of radiotherapy 
in steroid resistant cases(6). The response to radiation therapy is 
variable with sclerosing and granulomatous varieties respon-
ding poorly(1).
There is no clear consensus on the dose of radiation therapy. 
However most recommend using low dose radiation of less than 
10 Gy for orbital IP. 
Lee et al. assessed the response of skull base IP to steroids and 
radiation therapy. Their study showed poor response to both 
high dose corticosteroids and low-dose radiation therapy(6). 
They suggested that more aggressive approach should be used 
in the treatment of aggressive skull base IP with high dose radia-
tion with or without concurrent corticosteroids.
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Chemotherapy
Chemotherapeutic agents have shown modest success in 
steroid responsive patients. Agents used include azathioprine, 
cyclophosphamide and cyclosporine. Our patient who did not 
show any response to steroids initially, eventually responded 
well with an azathioprine and corticosteroid combination.
Multi-modality
Most extra orbital IP require multi-modality treatment. Patients 
who initially are steroid resistant can have significant clinical and 
radiological response to steroids after surgical decompression.
(10,16). A combination of cyberknife radiosurgery and rituximab, 
an anti-CD20 chimeric murine/human monoclonal antibody was 
used in a steroid resistant patient with good effect(4,16).
Brannan advocated using 2mg/kg oral prednisolone or intra-
venous methylprednisolone as initial treatment followed by 
radiotherapy and / or surgical debulking(24). Some have noted 
that incomplete surgical excision may result in worsening of 
symptoms caused by reactivation of the immune response. 
However, others argue that partial excision may provide signifi-
cant symptomatic relief secondary to an inflammatory ‘burnout’ 
phenomenon(16).
Cross et al. described a case of 53-year-old female with IP of 
the left submandibular gland, which was initially treated with 
surgery(17). Due to severe fibrosis and extension into skull base, 
carotid sheath and inferior border of the mandible, limited 
excision was performed and the patient was treated with high 
dose steroid post operatively. The patient had a good response 
but the disease recurred after cessation of treatment. She was 
treated again with low dose steroids and showed complete 
response.
Prognosis
Due to the relative rarity of significant case series or studies it is 
difficult to generalise about prognosis. However, it does appear 
to be linked to its histopathological and cellular classification 
as well as clinical presentation. IP may show a tendency toward 
spontaneous regression(9).
In some cases, the disease process progresses to and can lead to 
general deterioration of health leading to death. However, so far, 
IP has not been reported as direct cause of death(6).
Several cases in the literature found lymphoma in cases of IP 
after a chronic course(9). It is unclear whether these were missed 
diagnosed lesions or a genuine transformation within IP. In 
theory there is a risk of malignant transformation in lesions that 
show ganglion-like cells, p53 expression and aneuploidy but in 
the head and neck region there have been no reported cases of 
malignant change(7,25).
Conclusion
Idiopathic pseudotumours of the anterior skull base, although 
rare, present significant issues in their management. It can 
both clinically and radiologically mimic a neoplasm. Most of 
the information is based on the orbital pseudotumours but the 
extra-orbital and especially skull base IP is more aggressive and 
respond differently to conventional therapies. The literature is 
sparse on skull base IP but through case reports and series like 
ours we can improve our understanding of their behaviour and 
learn how to manage them effectively.
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